Latamoksef
Latamoksef je organsko jedinjenje, koje sadrži 20 atoma ugljenika i ima molekulsku masu od 520,473 Da.[1][2][3][4]
![]() | |
Klinički podaci | |
---|---|
Drugs.com | Monografija |
Farmakokinetički podaci | |
Poluvreme eliminacije | 1,6 h |
Izlučivanje | Renalno 75% |
Identifikatori | |
CAS broj | 64952-97-2 ![]() |
ATC kod | J01DD06 (WHO) |
PubChem | CID 47499 |
DrugBank | DB04570 ![]() |
ChemSpider | 43215 ![]() |
ChEBI | CHEBI:599928 ![]() |
ChEMBL | CHEMBL74632 ![]() |
Hemijski podaci | |
Formula | C20H20N6O9S |
Molarna masa | 520,473 |
| |
|
Osobine
уредиOsobina | Vrednost |
---|---|
Broj akceptora vodonika | 13 |
Broj donora vodonika | 4 |
Broj rotacionih veza | 9 |
Particioni koeficijent[5] (ALogP) | -0,6 |
Rastvorljivost[6] (logS, log(mol/L)) | -3,5 |
Polarna površina[7] (PSA, Å2) | 231,6 |
Reference
уреди- ^ Weitekamp MR, Aber RC: Prolonged bleeding times and bleeding diathesis associated with moxalactam administration. JAMA. 1983 Jan 7;249(1):69-71. PMID Weitekamp, M. R.; Aber, R. C. (1983). „Prolonged bleeding times and bleeding diathesis associated with moxalactam administration”. JAMA. 249 (1): 69—71. PMID 6217353. doi:10.1001/jama.1983.03330250049027.
- ^ Brown RB, Klar J, Lemeshow S, Teres D, Pastides H, Sands M: Enhanced bleeding with cefoxitin or moxalactam. Statistical analysis within a defined population of 1493 patients. Arch Intern Med. 1986 Nov;146(11):2159-64. PMID Brown, R. B.; Klar, J.; Lemeshow, S.; Teres, D.; Pastides, H.; Sands, M. (1986). „Enhanced bleeding with cefoxitin or moxalactam. Statistical analysis within a defined population of 1493 patients”. Archives of Internal Medicine. 146 (11): 2159—2164. PMID 3778044. doi:10.1001/archinte.1986.00360230079013.
- ^ Knox C, Law V, Jewison T, Liu P, Ly S, Frolkis A, Pon A, Banco K, Mak C, Neveu V, Djoumbou Y, Eisner R, Guo AC, Wishart DS (2011). „DrugBank 3.0: a comprehensive resource for omics research on drugs”. Nucleic Acids Res. 39 (Database issue): D1035—41. PMC 3013709 . PMID 21059682. doi:10.1093/nar/gkq1126.
- ^ Wishart, D. S.; Knox, C.; Guo, A. C.; Cheng, D.; Shrivastava, S.; Tzur, D.; Gautam, B.; Hassanali, M. (2008). „DrugBank: A knowledgebase for drugs, drug actions and drug targets”. Nucleic Acids Research. 36 (Database issue): D901—6. PMC 2238889 . PMID 18048412. doi:10.1093/nar/gkm958. Текст „noedit” игнорисан (помоћ)
- ^ Ghose, A.K.; Viswanadhan V.N. & Wendoloski, J.J. (1998). „Prediction of Hydrophobic (Lipophilic) Properties of Small Organic Molecules Using Fragment Methods: An Analysis of AlogP and CLogP Methods”. J. Phys. Chem. A. 102: 3762—3772. doi:10.1021/jp980230o.
- ^ Tetko, I. V.; Tanchuk, V. Y.; Kasheva, T. N.; Villa, A. E. (2001). „Estimation of aqueous solubility of chemical compounds using E-state indices”. Journal of Chemical Information and Computer Sciences. 41 (6): 1488—1493. PMID 11749573. doi:10.1021/ci000392t. Текст „noedit” игнорисан (помоћ)
- ^ Ertl, P.; Rohde, B.; Selzer, P. (2000). „Fast calculation of molecular polar surface area as a sum of fragment-based contributions and its application to the prediction of drug transport properties”. Journal of Medicinal Chemistry. 43 (20): 3714—3717. PMID 11020286. doi:10.1021/jm000942e. Текст „noedit” игнорисан (помоћ)
Literatura
уреди- Hardman JG, Limbird LE, Gilman AG (2001). Goodman & Gilman's The Pharmacological Basis of Therapeutics (10. изд.). New York: McGraw-Hill. ISBN 0071354697. doi:10.1036/0071422803.
- Thomas L. Lemke; David A. Williams, ур. (2007). Foye's Principles of Medicinal Chemistry (6. изд.). Baltimore: Lippincott Willams & Wilkins. ISBN 0781768799.
Spoljašnje veze
уреди
Molimo Vas, obratite pažnju na važno upozorenje u vezi sa temama iz oblasti medicine (zdravlja). |